Telix Pharmaceuticals Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Telix Pharmaceuticals Ltd (TLX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Telix Pharmaceuticals Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 804M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+299.8% annualized vs trailing 12 months).
- Scale: Telix Pharmaceuticals Ltd ranks #69 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.1% of industry market cap.
- Peer revenue share: Telix Pharmaceuticals Ltd accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TLX Sales vs. its Competitors, Q4 2025
Telix Pharmaceuticals Ltd generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 2.7% for Telix Pharmaceuticals Ltd. Telix Pharmaceuticals Ltd's share of combined industry revenue moved from 0.17% to 0.16%, a loss of 0.01 percentage points.
Telix Pharmaceuticals Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Telix Pharmaceuticals Ltd | No | Yes | Yes | Yes |
| High-Confidence Competitors (4) | - | |||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 42.90 % (3 of 7) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TLX Stock Performance relative to its Competitors
TLX Stock Performance relative to High-Confidence Competitors
TLX Stock Performance relative to Similar-Size Competitors
TLX Stock Performance relative to Similar Growth & Profitability Competitors
Telix Pharmaceuticals Ltd's Comment on Competition and Industry Peers
Telix Pharmaceuticals Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Named by the company | 85% |
| Fusion Pharmaceuticals Inc | Named by the company | 85% |
| Qsam Biosciences Inc | Named by the company | 85% |
| Vivos Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Telix Pharmaceuticals Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.